TY - JOUR
T1 - Parkinsonism and spastic paraplegia type 7: Expanding the spectrum of mitochondrial Parkinsonism
AU - De la Casa-Fages, Beatriz
AU - Fernández-Eulate, Gorka
AU - Gamez, Josep
AU - Barahona-Hernando, Raúl
AU - Morís, Germán
AU - García-Barcina, María
AU - Infante, Jon
AU - Zulaica, Miren
AU - Fernández-Pelayo, Uxoa
AU - Muñoz-Oreja, Mikel
AU - Urtasun, Miguel
AU - Olaskoaga, Ander
AU - Zelaya, Victoria
AU - Jericó, Ivonne
AU - Saez-Villaverde, Raquel
AU - Catalina, Irene
AU - Sola, Emma
AU - Martínez-Sáez, Elena
AU - Pujol, Aurora
AU - Ruiz, Montserrat
AU - Schlüter, Agatha
AU - Spinazzola, Antonella
AU - Muñoz-Blanco, Jose Luis
AU - Grandas, Francisco
AU - Holt, Ian
AU - Álvarez, Victoria
AU - López de Munaín, Adolfo
N1 - © 2019 International Parkinson and Movement Disorder Society.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - © 2019 International Parkinson and Movement Disorder Society Background: Pathogenic variants in the spastic paraplegia type 7 gene cause a complicated hereditary spastic paraplegia phenotype associated with classical features of mitochondrial diseases, including ataxia, progressive external ophthalmoplegia, and deletions of mitochondrial DNA. Objectives: To better characterize spastic paraplegia type 7 disease with a clinical, genetic, and functional analysis of a Spanish cohort of spastic paraplegia type 7 patients. Methods: Genetic analysis was performed in patients suspecting hereditary spastic paraplegia and in 1 patient with parkinsonism and Pisa syndrome, through next-generation sequencing, whole-exome sequencing, targeted Sanger sequencing, and multiplex ligation-dependent probe analysis, and blood mitochondrial DNA levels determined by quantitative polymerase chain reaction. Results: Thirty-five patients were found to carry homozygous or compound heterozygous pathogenic variants in the spastic paraplegia type 7 gene. Mean age at onset was 40 years (range, 12–63); 63% of spastic paraplegia type 7 patients were male, and three-quarters of all patients had at least one allele with the c.1529C>T (p.Ala510Val) mutation. Eighty percent of the cohort showed a complicated phenotype, combining ataxia and progressive external ophthalmoplegia (65% and 26%, respectively). Parkinsonism was observed in 21% of cases. Analysis of blood mitochondrial DNA indicated that both patients and carriers of spastic paraplegia type 7 pathogenic variants had markedly lower levels of mitochondrial DNA than control subjects (228 per haploid nuclear DNA vs. 176 vs. 573, respectively; P < 0.001). Conclusions: Parkinsonism is a frequent finding in spastic paraplegia type 7 patients. Spastic paraplegia type 7 pathogenic variants impair mitochondrial DNA homeostasis irrespective of the number of mutant alleles, type of variant, and patient or carrier status. Thus, spastic paraplegia type 7 supports mitochondrial DNA maintenance, and variants in the gene may cause parkinsonism owing to mitochondrial DNA abnormalities. Moreover, mitochondrial DNA blood analysis could be a useful biomarker to detect at risk families. © 2019 International Parkinson and Movement Disorder Society.
AB - © 2019 International Parkinson and Movement Disorder Society Background: Pathogenic variants in the spastic paraplegia type 7 gene cause a complicated hereditary spastic paraplegia phenotype associated with classical features of mitochondrial diseases, including ataxia, progressive external ophthalmoplegia, and deletions of mitochondrial DNA. Objectives: To better characterize spastic paraplegia type 7 disease with a clinical, genetic, and functional analysis of a Spanish cohort of spastic paraplegia type 7 patients. Methods: Genetic analysis was performed in patients suspecting hereditary spastic paraplegia and in 1 patient with parkinsonism and Pisa syndrome, through next-generation sequencing, whole-exome sequencing, targeted Sanger sequencing, and multiplex ligation-dependent probe analysis, and blood mitochondrial DNA levels determined by quantitative polymerase chain reaction. Results: Thirty-five patients were found to carry homozygous or compound heterozygous pathogenic variants in the spastic paraplegia type 7 gene. Mean age at onset was 40 years (range, 12–63); 63% of spastic paraplegia type 7 patients were male, and three-quarters of all patients had at least one allele with the c.1529C>T (p.Ala510Val) mutation. Eighty percent of the cohort showed a complicated phenotype, combining ataxia and progressive external ophthalmoplegia (65% and 26%, respectively). Parkinsonism was observed in 21% of cases. Analysis of blood mitochondrial DNA indicated that both patients and carriers of spastic paraplegia type 7 pathogenic variants had markedly lower levels of mitochondrial DNA than control subjects (228 per haploid nuclear DNA vs. 176 vs. 573, respectively; P < 0.001). Conclusions: Parkinsonism is a frequent finding in spastic paraplegia type 7 patients. Spastic paraplegia type 7 pathogenic variants impair mitochondrial DNA homeostasis irrespective of the number of mutant alleles, type of variant, and patient or carrier status. Thus, spastic paraplegia type 7 supports mitochondrial DNA maintenance, and variants in the gene may cause parkinsonism owing to mitochondrial DNA abnormalities. Moreover, mitochondrial DNA blood analysis could be a useful biomarker to detect at risk families. © 2019 International Parkinson and Movement Disorder Society.
KW - hereditary spastic paraplegia
KW - mitochondria
KW - parkinsonism
KW - pathogenic genetic variants
KW - SPG7 gene
KW - HOMEOSTASIS
KW - PROTEIN
KW - SUBSTANTIA-NIGRA
KW - IMPAIRMENT
KW - GENE
KW - SPG7 MUTATIONS
KW - DISEASE
KW - DNA DELETIONS
UR - http://www.mendeley.com/research/parkinsonism-spastic-paraplegia-type-7-expanding-spectrum-mitochondrial-parkinsonism
UR - https://www.scopus.com/pages/publications/85070938272
U2 - 10.1002/mds.27812
DO - 10.1002/mds.27812
M3 - Article
C2 - 31433872
SN - 0885-3185
VL - 34
SP - 1547
EP - 1561
JO - Movement Disorders
JF - Movement Disorders
IS - 10
ER -